Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

randomized double-blind controlled study in parallel groups

Salbutamol is a β2 mimetic short-acting to be administered by nebulization in this study.

During this administration, non invasive ventilation for the patient will be continued.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Tours
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• Patient over 18 years old

• Patient with BPCO, defined:

• by an irreversible obstructive syndrome

• and\or by different arguments (histories, symptoms, physical examination, thoracic radiography, gas of the blood)

• Decompensation of this BPCO in the form of acute respiratory failure

• No argument for a dominant acute left cardiac insufficiency

• Consent signed by the patient

• Patient with national health assurance

Exclusion Criteria:

• Contraindications in the not invasive ventilation

• Patient not volunteer for the realization of the spirometry

• Precautions for use of ß2 mimetic (engrave hyperthyroidism)

• Under guardianship patient or protection of justice

• Pregnant patient